News
Pedersen and Maggie Fick COPENHAGEN (Reuters) -As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the ...
Hyderabad-based Natco Pharma has filed a lawsuit against Danish drugmaker Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy (semaglutide), before the Delhi High Court.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...
Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...
Shares in Novo Nordisk, which makes Wegovy and Ozempic, are down 45pc so far this year as it battles competition from rival ...
GLP-1 drugs promote weight loss by reducing appetite and causing the stomach to empty more slowly. Novo Nordisk's Wegovy and ...
Hyderabad-based Natco Pharma, through its legal representative, reportedly stated that it had reached out to the Danish drugmaker multiple times in recent months to discuss its non-infringing patents ...
Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...
Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...
As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results